| Celularity Inc. | William van der Touw | A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19 |
$315,000 |
| University of California, San Francisco | Dr. Michael Matthay MD | Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
$701,049 |
| City of Hope, Beckman Research Institute | Prof. John A. Zaia | Evaluation and Characterization of SARS-CoV-2 Antibody in Convalescent Volunteer Plasma Donors for Potential Therapeutic Use |
$999,999 |
